Crypto Market Cap, BTC/USD, ETH/USD, USDT/USD, XRP/USD, Bitcoin
Apple, Advanced Micro Devices Inc, Amazon Com Inc, TESLA INC, NETFLIX INC, Facebook Inc
S&P 500, Nasdaq 100, Dow 30, Russell 2000, U.S. Dollar Index, Bitcoin Index
US 10Y, Euro Bund, Germany 10Y, Japan 10Y Yield, UK 10Y, India 10Y
MYGN: Myriad Genetics, Inc. 2020-05-11 07:05:10 Myriad Receives FDA Approval of myChoice CDx® as Companion Diagnostic for Lynparza™ (olaparib) In Patients with Advanced Ovarian Cancer
I thought about it and didn't publish this because my earnings plays for today didn't play out like it should have. CENT and USX both lost money but apparently "beat estimates", which is hilarious when the estimate is a loss. You'd think they were tech companies or something. At least CENT went down after a short squeeze rally, and we nailed XYL. In the end I...
MYGN has been a player for a while, large company, with actual earnings, however litigation and companies are generally a bad thing. "healthy" enough of a chart for me to participate, but I will not have much patience to the downside, stop in place. **Long this last collapse, limited in size... confidence is enough to buy, not enough to bet the farm
MYGN: Myriad Genetics, Inc. 2019-10-23 17:40:52 FDA Approves Myriad’s myChoice® CDx Test to Help Identify Women Eligible for Treatment with Zejula® in Late-line Ovarian Cancer
I think this stock will recover some of it's losses, regardless of the outcome of the potential FDA restrictions on drug suggestions. The stock has a solid business model and the company has said they are seeing increased demand. This new fields of genetics testing still needs to establish itself in the healthcare payer ecosystem, which presents some risk, but all...
In at $33.29. 1 ATR stop in place. Target = 20% Bearish engulfing. Biotech sector bearish.
MYGN: Myriad Genetics, Inc. 2018-11-19 07:05:00 Myriad Announces $50 Million Accelerated Share Repurchase Program
MYGN is setting up a long term H&S. An aggressive sell option is triggering today on the close below the old pivot low with the stop past the head. H&S will not trigger until a break of the neckline near $27. Aggressive right shoulder buy and sell's fail, but the greatly increased risk/reward can help offset.
MYGN Price broke out from 2 1/2 months of a base formation. A price gap of nearly 10% with very high volume occurred as a result of better-than-expected earnings. Unfortunately, we shouldn't expect the Tight Flag pattern to be powerful, since it is coming out of a base formation pattern, and not a powerful uptrend, but there should be enough upside potential to...
MYGN is another nice Flag formation with beautiful moneyflow accumulation. Anything close to $18 would be a good entry point or break of current label * Trade Criteria * Date First Found- February 19, 2017 Pattern/Why- Flag formation Entry Target Criteria- Near $18 or Break of $18.67 Exit Target Criteria- Momentum Stop Loss Criteria- $16.83 Please check...
As the price is revisiting the US$18.76 resistance, we may expect a short term pullback. However, overall trend can be considered as positive. We may look for opportunity around the US$17-US$18 levels for accumulation. Target: US$21.40-22.40, US$26.15-US$28.58. Support: US$16.47
MYGN took a beating after it's guidance underwhelm last quarter. I do believe that the reaction was overdone. MYGN has healthy revenue streams and growing drug and generics demand. TA confirms a re-entering into trading range of: PT 1: $25.00 for a ~20%+ return. PT 2: $30.00 for a 50% return.